Seres Therapeutics Ready to Breakout?

NASDAQ: MCRB | Seres Therapeutics, Inc. News, Ratings, and Charts

MCRB – Seres Therapeutics (MCRB) is approaching a key level of resistance in its chart. If the stock breaks through this level, a breakout could soon occur. Read more to learn how to take advantage of this trade.

Seres Therapeutics Inc. (MCRB) is approaching a key level of resistance.  If this level is surpassed, a breakout could occur.

MCRB is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics.

The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. MCRB has six drugs in various stages of development. These range from drugs that fight Clostridium difficile, or C diff, and colitis to metastatic melanoma.

The company had $254 million in cash and short-term investments at the end of last year, compared with no short-term debt. But MCRB currently has a negative profit margin. MCRB’s hasn’t shown positive earnings over the last six years, but sales were up 130.4% year over year in the most recent quarter.

Based on its price-to-sales and price-to-book ratios, the company is currently overvalued. The stock was trending lower from February 7th to March 3rd, but has shown mixed performance since.

Take a look at the 1-year chart of MCRB below with the added notations:

  Chart of MCRB provided by TradingView

Over the past nine months, MCRB has formed an important level to watch at the $22.50 (blue) mark. This level has provided both support and resistance repeatedly.

MCRB is currently sitting just under that level now, and a rally higher could bring another $22.50 resistance test. A trader could enter a long trade a break back above the $22.50 mark with the expectation of a breakout..

Want to Discover More Great Trades?

I have explored virtually every flavor of technical analysis and chart pattern known to mankind. The sad fact is that the vast majority of them don’t work at all.

That is why I recently put together this special report to help investors focus on the only 5 chart patterns that matter…the ones that lead to the most timely and profitable stock trades. Click below to get your copy now!

5 WINNING Stock Chart Patterns

Have a good trading day!

Good luck!

Christian Tharp, CMT

@cmtstockcoach


MCRB shares were unchanged in premarket trading Monday. Year-to-date, MCRB has declined -15.39%, versus a 11.71% rise in the benchmark S&P 500 index during the same period.


About the Author: Christian Tharp


I am an expert stock market coach having helped over 4000 beginner and advanced traders & investors from around the world take control of their financial futures. I also write stock market related articles for the Adam Mesh Trading Group and Yolo Publishing. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MCRBGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

The Fallacy of “Peak Everything”

Connected to the inflation conversation is the theory of “Peak Everything”. This idea is making its rounds through the investing world with shock waves of trading activity. Let’s talk about what it is...What it really means for the future of the S&P 500 (SPY)...And why, we will end up on the right side of action. Read on below to find out more…

:  |  News, Ratings, and Charts

Could the Fed’s Rate Reversal Lead to More Volatility in the Stock Market?

Inflation has become a recurring theme in my comments due to a notable rise in inflation metrics and how they have affected the S&P 500 (SPY). The Fed has consistently spoken of inflation being transitory over the past couple of months, which has resulted in investors becoming less concerned over higher prices. But it appeared that the Fed reversed course as it is now, indicating it would raise rates ahead of schedule. This created more volatility in the markets leading to a tough day on Friday. But, if you look closer at their remarks, not everything is as it seems. I will expand on my point below. But first, let's recap the past week in the markets. Read on below…

:  |  News, Ratings, and Charts

2nd Half of 2021 Stock Market Outlook

The stock market (SPY) has continued on a bullish path to start 2021. Yet it is not quite the same glorious bull run we enjoyed from the lows of last year. This market has become more volatile and with less upside potential. However, there is still plenty of money to be made if you look in the right places. That is the very nature of the new presentation I put together. So read on for more info…

:  |  News, Ratings, and Charts

3 Top Biotech Stocks To Bolster Your Portfolio

Illumina (ILMN), Jazz Pharmaceuticals (JAZZ), and Amgen (AMGN) are 3 of the top biotech stocks. The sector has been an underperformer over the last few years but could start outperforming given the aging population, low valuation, and growth potential.

:  |  News, Ratings, and Charts

2nd Half of 2021 Stock Market Outlook

The stock market (SPY) has continued on a bullish path to start 2021. Yet it is not quite the same glorious bull run we enjoyed from the lows of last year. This market has become more volatile and with less upside potential. However, there is still plenty of money to be made if you look in the right places. That is the very nature of the new presentation I put together. So read on for more info…

Read More Stories

More Seres Therapeutics, Inc. (MCRB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MCRB News